Genome Past Earnings Performance
Past criteria checks 0/6
Genome has been growing earnings at an average annual rate of 4.3%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 77.8% per year.
Key information
4.3%
Earnings growth rate
22.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 77.8% |
| Return on equity | -43.8% |
| Net Margin | -283.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Revenue & Expenses Breakdown
How Genome makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 16,011 | -45,334 | 29,127 | 22,996 |
| 31 Dec 23 | 14,296 | -47,466 | 28,677 | 25,666 |
| 30 Sep 23 | 14,552 | -39,581 | 21,379 | 28,177 |
| 30 Jun 23 | 14,987 | -42,685 | 21,230 | 31,242 |
| 31 Mar 23 | 13,877 | -52,642 | 20,991 | 36,875 |
| 31 Dec 22 | 14,085 | -51,838 | 19,664 | 36,793 |
| 30 Sep 22 | 10,384 | -48,011 | 20,005 | 32,128 |
| 30 Jun 22 | 5,599 | -45,513 | 17,474 | 30,939 |
| 31 Mar 22 | 3,063 | -36,268 | 14,921 | 23,278 |
| 31 Dec 21 | 451 | -34,117 | 14,123 | 21,263 |
| 30 Sep 21 | 371 | -29,860 | 11,822 | 20,292 |
| 30 Jun 21 | 308 | -45,186 | 13,676 | 16,728 |
| 31 Mar 21 | 292 | -33,406 | 13,536 | 16,593 |
| 31 Dec 20 | 151 | -30,732 | 12,915 | 13,669 |
| 31 Dec 19 | 46 | -84,669 | 5,933 | 7,773 |
Quality Earnings: A314130 is currently unprofitable.
Growing Profit Margin: A314130 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A314130 is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare A314130's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A314130 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A314130 has a negative Return on Equity (-43.81%), as it is currently unprofitable.